DrugPatentWatch Database Preview
WAKIX Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Wakix patents expire, and what generic alternatives are available?
Wakix is a drug marketed by Harmony and is included in one NDA. There are five patents protecting this drug.
This drug has eighty-three patent family members in thirty-three countries.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this compound. Additional details are available on the pitolisant hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Wakix
Wakix will be eligible for patent challenges on August 14, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for WAKIX
| International Patents: | 83 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 40 |
| Patent Applications: | 19 |
| DailyMed Link: | WAKIX at DailyMed |
Generic Entry Opportunity Date for WAKIX
Generic Entry Date for WAKIX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for WAKIX
| 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine |
| 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine |
| 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride |
| 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine |
| 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine |
| 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether |
| 362665-56-3 |
| 3973AH |
| 4BC83L4PIY |
| AKOS028108820 |
| API0014072 |
| BCP13114 |
| BDBM50247053 |
| BF2.649 |
| CHEBI:134709 |
| CHEMBL462605 |
| CS-0666 |
| CTK1B6404 |
| D10749 |
| DTXSID30957654 |
| GTPL8924 |
| HBS-101 |
| HMS3743C05 |
| HY-12199 |
| KS-000002GS |
| MFCD18782650 |
| NNACHAUCXXVJSP-UHFFFAOYSA-N |
| Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- |
| Pitolisant |
| Pitolisant (BF2.649) |
| Pitolisant (USAN/INN) |
| Pitolisant [USAN:INN] |
| SB17037 |
| SCHEMBL117648 |
| TIPROLISANT |
| tiprolisant [USAN] |
| Tirolisant |
| UNII-4BC83L4PIY |
| W-5790 |
| Wakix (TN) |
| ZINC34045468 |
US Patents and Regulatory Information for WAKIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for WAKIX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Serbia | 52911 | Start Trial |
| China | 101171009 | Start Trial |
| European Patent Office | 1428820 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for WAKIX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1428820 | 16C0038 | France | Start Trial | PRODUCT NAME: PITOLISANT ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/15/1068 20160331 |
| 1428820 | SPC/GB16/052 | United Kingdom | Start Trial | PRODUCT NAME: PITOLISANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SUCH AS HYDROCHLORIDE; REGISTERED: UK EU/1/15/1068 20160404 |
| 1428820 | 1690039-1 | Sweden | Start Trial | PRODUCT NAME: PITOLISANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SUCH AS HYDROCHLORIDE.; REG. NO/DATE: EU/15/1068 20160404 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
